BRPI0512086A - composto e os sais farmacologicamente aceitáveis do mesmo, composição farmacêutica, e, processo para a preparação de compostos - Google Patents

composto e os sais farmacologicamente aceitáveis do mesmo, composição farmacêutica, e, processo para a preparação de compostos

Info

Publication number
BRPI0512086A
BRPI0512086A BRPI0512086-1A BRPI0512086A BRPI0512086A BR PI0512086 A BRPI0512086 A BR PI0512086A BR PI0512086 A BRPI0512086 A BR PI0512086A BR PI0512086 A BRPI0512086 A BR PI0512086A
Authority
BR
Brazil
Prior art keywords
compounds
acceptable salts
compound
preparation
pharmaceutically acceptable
Prior art date
Application number
BRPI0512086-1A
Other languages
English (en)
Inventor
Jan Bergman
Robert Engqvist
Bengt Gerdin
Ingemar Kihlstroem
Ulf Bjoerklund
Original Assignee
Oxypharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxypharma Ab filed Critical Oxypharma Ab
Publication of BRPI0512086A publication Critical patent/BRPI0512086A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

COMPOSTO E OS SAIS FARMACOLOGICAMENTE ACEITáVEIS DO MESMO, COMPOSIçãO FARMACêUTICA, E, PROCESSO PARA A PREPARAçãO DE COMPOSTOS Indoloquinoxalinas substituídas novas da fórmula (IR¬ 2¬ (I)¬ Y¬ onde R¬ 1¬ é hidrogênio ou representa um ou mais substituintes semelhantes ou diferentes nas posições 7 a 10 escolhidos do grupo de halogênio, alquil/alcóxi inferior, hidróxi, trifluorometila, triclorometila, trifluorometóxi, R¬ 2¬ representa alquil substituintes C~ 1~ -C~ 4~ semelhantes ou diferentes, X é CO ou CH~ 2~, Y é OH, NH~ 2~, NH-(CH~ 2~)~ n~ -R¬ 3¬ onde R¬ 3¬ representa alquila inferior, OH, NH~ 2~, NHR¬ 4¬ ou NR¬ 5¬ R¬ 6¬ onde R¬ 4¬, R¬ 5¬ e R¬ 6¬, independentemente, são alquila ou cicloalquila inferior e n é um número inteiro de 2 a 4, com a condição de que quando X é CH~ 2~, Y é OH ou NH-(CH~ 2~)~ n~ -OH, e os sais farmacologicamente aceitáveis dos mesmos, são descritos. Os compostos são úteis como drogas para evitar e/ou tratar doenças autoimunes.
BRPI0512086-1A 2004-06-17 2005-05-18 composto e os sais farmacologicamente aceitáveis do mesmo, composição farmacêutica, e, processo para a preparação de compostos BRPI0512086A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0401555A SE527639C2 (sv) 2004-06-17 2004-06-17 Alkylsubstituerade indolokinoxaliner
PCT/SE2005/000718 WO2005123741A1 (en) 2004-06-17 2005-05-18 Alkyl substituted indoloquinoxalines

Publications (1)

Publication Number Publication Date
BRPI0512086A true BRPI0512086A (pt) 2008-02-06

Family

ID=32710074

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512086-1A BRPI0512086A (pt) 2004-06-17 2005-05-18 composto e os sais farmacologicamente aceitáveis do mesmo, composição farmacêutica, e, processo para a preparação de compostos

Country Status (23)

Country Link
US (2) US7589093B2 (pt)
EP (1) EP1756111B1 (pt)
JP (1) JP5038891B2 (pt)
CN (1) CN1976934B (pt)
AT (1) ATE462707T1 (pt)
AU (1) AU2005254919B2 (pt)
BR (1) BRPI0512086A (pt)
CA (1) CA2568592C (pt)
CY (1) CY1110145T1 (pt)
DE (1) DE602005020283D1 (pt)
DK (1) DK1756111T3 (pt)
ES (1) ES2342946T3 (pt)
IL (1) IL179171A (pt)
MX (1) MXPA06014170A (pt)
NO (1) NO20070289L (pt)
NZ (1) NZ551780A (pt)
PL (1) PL1756111T3 (pt)
PT (1) PT1756111E (pt)
RU (1) RU2369609C2 (pt)
SE (1) SE527639C2 (pt)
SI (1) SI1756111T1 (pt)
WO (1) WO2005123741A1 (pt)
ZA (1) ZA200700358B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE529777C2 (sv) * 2006-01-23 2007-11-20 Vironova Ab Nya föreningar och användning därav
JP5454750B2 (ja) 2008-03-05 2014-03-26 東洋製罐株式会社 缶詰の内圧検査方法及びその装置
DE602008001795D1 (de) 2008-04-30 2010-08-26 Univ Duisburg Essen IndolÄ2,3-bÜ-, IndenÄ1,2-bÜ- und IndenÄ2,1-bÜpyridoÄ2,3-fÜ Quinoxalin-3-Carboxylsäuren und Ester, Verfahren zu ihrer Herstellung und ihre Verwendung als Antivirus- und Antitumormittel
EP2489354A1 (en) * 2011-02-18 2012-08-22 Vironova AB Pharmaceutical formulation of B220 for topical treatment of herpes
CN103211960B (zh) * 2012-01-18 2017-10-13 金士力佳友(天津)有限公司 具有降血糖作用的中药组合物、其应用及制备方法
SG11201507310VA (en) * 2013-03-15 2015-10-29 Vironova Herpes Ab Antiviral indolo[2,3-b]quinoxaline
WO2021250196A1 (en) * 2020-06-10 2021-12-16 Cyxone Ab New use of rabeximod
EP4165043A1 (en) * 2020-06-10 2023-04-19 Cyxone AB Method for preparing a crystalline form of rabeximod
CN116323614A (zh) 2020-09-21 2023-06-23 维洛诺瓦医药公司 用于治疗炎性和自身免疫性病症的rabeximod的硫羰酯衍生物
US11643415B1 (en) 2021-12-09 2023-05-09 Cyxone Ab Rabeximod compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE504862C2 (sv) * 1994-12-27 1997-05-20 Leif J I Lundblad Användning av vissa indolo-§2,3b¤-kinoxaliner för framställning av ett läkemedel för skydd av DNA i initieringsfasen och/eller promotionsfasen av karcinogenes och för förhindrande av oxidativ stress i patienter med sjukdomar relaterade till fria radikaler
US6333327B2 (en) * 2000-02-18 2001-12-25 Leif J. I. Lundblad Method for the treatment of Multiple Sclerosis
SE516067C2 (sv) * 2000-02-18 2001-11-12 Lundblad Leif J I Användning av en förening för framställning av ett läkemedel

Also Published As

Publication number Publication date
JP5038891B2 (ja) 2012-10-03
RU2369609C2 (ru) 2009-10-10
AU2005254919A1 (en) 2005-12-29
CA2568592C (en) 2012-10-30
DK1756111T3 (da) 2010-07-12
SE527639C2 (sv) 2006-05-02
ES2342946T3 (es) 2010-07-19
WO2005123741A1 (en) 2005-12-29
US20110086859A9 (en) 2011-04-14
US20100009999A1 (en) 2010-01-14
AU2005254919B2 (en) 2011-07-21
US7589093B2 (en) 2009-09-15
RU2007101497A (ru) 2008-07-27
IL179171A (en) 2012-12-31
EP1756111B1 (en) 2010-03-31
SE0401555D0 (sv) 2004-06-17
PT1756111E (pt) 2010-06-01
ATE462707T1 (de) 2010-04-15
CN1976934A (zh) 2007-06-06
ZA200700358B (en) 2008-07-30
DE602005020283D1 (de) 2010-05-12
SI1756111T1 (sl) 2010-08-31
US20050288296A1 (en) 2005-12-29
EP1756111A1 (en) 2007-02-28
US8084453B2 (en) 2011-12-27
PL1756111T3 (pl) 2010-08-31
NO20070289L (no) 2007-01-16
CA2568592A1 (en) 2005-12-29
MXPA06014170A (es) 2007-05-09
JP2008502676A (ja) 2008-01-31
NZ551780A (en) 2010-05-28
SE0401555L (sv) 2005-12-18
IL179171A0 (en) 2007-03-08
CN1976934B (zh) 2013-05-29
CY1110145T1 (el) 2015-01-14

Similar Documents

Publication Publication Date Title
BRPI0512086A (pt) composto e os sais farmacologicamente aceitáveis do mesmo, composição farmacêutica, e, processo para a preparação de compostos
CY1122863T1 (el) Φαρμακευτικη συνθεση που περιεχει γλυκοπυρρολικο και εναν αγωνιστη βητα2 αδρενοϋποδοχεα
ATE437872T1 (de) Proteinkinaseinhibitoren
RS20090249A (en) Spiroketone acetyl-coa carboxylase inhibotors
HK1068334A1 (en) Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
RS20050469A (en) Pyrrolopyrimidine derivatives
CA2545427A1 (en) Selective kinase inhibitors
SG128491A1 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
ATE457988T1 (de) A2a-adenosin-rezeptor-antagonisten
ECSP066948A (es) Benzoxazinas para el tratamiento de enfermedades de las vías respiratorias
BRPI0608732A2 (pt) composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto
CL2004000382A1 (es) Tetrahidroisoquinolinas sustituidas, proceso de preparacion, y composicion farmaceutica, utiles en el tratamiento y prevencion de estados patologicos que se alivian con un agonista de 5-ht6.
ATE471323T1 (de) Purinderivate als antagonisten an purinergen rezeptoren
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
SE0401342D0 (sv) Therapeutic compounds
CY1108632T1 (el) Παραγωγα της 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline για θεραπεια της στειροτητας
ATE435223T1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
HRP20080119T5 (en) Benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same
AR044175A1 (es) Compuestos de cefemo
BRPI0513549A (pt) composições farmacêuticas para o tratamento de leishmaniose
RU2003113145A (ru) Замещенные 5r1, 6r2-1, 3,4-тиадиазин-2, амины и содержащие их фармацевтические композиции в качестве фармакологически активных средств, обладающих антикоагулятным и антиагрегатным действием
WO2006029075A8 (en) Fibrate compounds having ppar agonist activity
TW200614991A (en) Novel compounds
TW200626583A (en) Novel compounds

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2308 DE 31/03/2015.